| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [2] |
Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer[J]. Lancet, 2024, 404(10449): 294-310.
|
| [3] |
Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial[J]. Nat Med, 2024, 30(4): 1035-1043.
|
| [4] |
Khudeir JF, Elkord E. Unmasking cancer’s silent saboteurs: T regulatory cells as therapeutic targets in immunotherapy[J]. Expert Rev Clin Immunol, 2025, 21(11): 1583-600.
|
| [5] |
Li D, Liu J, Yu L, et al. Integrated single-cell RNA-Seq reveals immunosuppressive mechanisms of Treg cell differentiation and tumor microenvironment interactions in colorectal cancer[J]. Cancer Med, 2025, 14(17): e71202.
|
| [6] |
Benoist C, Flavell RA, Mathis D, et al. The history and promise of Treg cells[J]. Immunity, 2025, 58(12): 2934-2939.
|
| [7] |
Estrada Brull A, Joller N. From chaos to control: nobel insights in regulatory T cells and immune tolerance[J]. Pflugers Arch, 2025, 478(1): 5.
|
| [8] |
Jugder BE, Park E, Du L, et al. Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications[J]. Front Immunol, 2025, 16: 1650451.
|
| [9] |
Lui PP, Cho I, Ali N. Tissue regulatory T cells[J]. Immunology, 2020, 161(1): 4-17.
|
| [10] |
Wang L, Liang Y, Zhao C, et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential[J]. Signal Transduct Target Ther, 2025, 10(1): 345.
|
| [11] |
Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases[J]. Nat Rev Immunol, 2024, 24(7): 503-517.
|
| [12] |
Hu W, Dolsten GA, Wang EY, et al. Temporal and context-dependent requirements for the transcription factor Foxp3 expression in regulatory T cells[J]. Nat Immunol, 2025, 26(11): 2059-2073.
|
| [13] |
Voß LC, Schmidt C, Harberts A, et al. Interferon regulatory factor 4 dose-dependently controls peripheral Treg cell differentiation and homeostasis by modulating chromatin accessibility in mice[J]. Front Immunol, 2025, 16: 1604888.
|
| [14] |
Peng Y, Tao Y, Zhang Y, et al. CD25: a potential tumor therapeutic target[J]. Int J Cancer, 2023, 152(7): 1290-1303.
|
| [15] |
Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy[J]. Cancer Cell, 2023, 41(3): 450-465.
|
| [16] |
Li D, Liu J, Yu L, Luo X, et al. Integrated single-cell RNA-Seq reveals immunosuppressive mechanisms of Treg cell differentiation and tumor microenvironment interactions in colorectal cancer[J]. Cancer Med, 2025, 14(17): e71202.
|
| [17] |
Tan SN, Hao J, Ge J, et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39[J]. J Exp Med, 2025, 222(4): e20240445.
|
| [18] |
Lu Y, Li Y, Liu Q, et al. MondoA-thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment[J]. Gastroenterology, 2021, 161(2): 575-591.e16.
|
| [19] |
You S, Li S, Zeng L, et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity[J]. Cancer Cell, 2024, 42(8): 1415-1433.e12.
|
| [20] |
Li J, Wu C, Hu H, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer[J]. Cancer Cell, 2023, 41(6): 1152-1169.e7.
|
| [21] |
Wang A, Huang H, Shi JH, et al. USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis[J]. J Clin Invest, 2023, 133(23): e169365.
|
| [22] |
Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J]. Cancer Cell, 2022, 40(2): 201-218.e9.
|
| [23] |
Solomon I, Amann M, Goubier A, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity[J]. Nat Cancer, 2020, 1(12): 1153-1166.
|
| [24] |
Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy[J]. Eur J Immunol, 2023, 53(1): e2250034.
|
| [25] |
Chen Q, Shen M, Yan M, et al. Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer[J]. J Transl Med, 2024, 22(1): 709.
|
| [26] |
Wen Y, Xia Y, Yang X, et al. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells[J]. Trends Immunol, 2025, 46(2): 153-165.
|
| [27] |
Shen K, Song W, Wang H, et al. Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score[J]. Cell Death Discov, 2023, 9(1): 397.
|
| [28] |
Kang X, Li Y, Han Y, et al. Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer[J]. Mol Ther, 2025, 33(9): 4600-4617.
|
| [29] |
Guo R, Wang Y, Sun J, et al. Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity[J]. Front Immunol, 2025, 16: 1637317.
|
| [30] |
Bündgen G, Ulges A, Pietruschka J, et al. Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells[J]. Immunity, 2025, 58(8): 2019-2034. e11.
|
| [31] |
Shiri AM, Fard-Aghaie M, Bedke T, et al. Foxp3 + Treg-derived IL-10 promotes colorectal cancer-derived lung metastasis[J]. Sci Rep, 2024, 14(1): 30483.
|
| [32] |
Li Y, Singh N, Dong C, et al. Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy[J]. Sci Immunol, 2025, 10(110): eadr9933.
|
| [33] |
Long X, Zhang S, Wang Y, et al. Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity[J]. Nat Immunol, 2024, 25(3): 525-536.
|
| [34] |
Zhang J, Huang D, Saw PE, et al. Turning cold tumors hot: from molecular mechanisms to clinical applications[J]. Trends Immunol, 2022, 43(7): 523-545.
|
| [35] |
Kidani Y, Nogami W, Yasumizu Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory[J]. Proc Natl Acad Sci USA, 2022, 119(7): e2114282119.
|
| [36] |
Zhang J, Sun L, Jiang L, et al. Regulation of CTLs/Tregs via highly stable and ultrasound-responsive cerasomal nano-modulators for enhanced colorectal cancer immunotherapy[J]. Adv Sci (Weinh), 2024, 11(22): e2400485.
|